Clinical trials: Chronic Pulmonary Obstruction
Insomnia
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
This study will evaluate the safety, tolerability, and effect of multiple doses of suvorexant (MK-4305) on respiratory function in participants with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01293006
- Testing
- suvorexant
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Obstructive Pulmonary Disease (COPD)
Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol
The purpose of the study is to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily budesonide for 12 weeks in COPD patients on a background therapy of formoterol.
- Trial name
- NCT01555099
- Testing
- AZD5423, Budesonide
- Where
- 44 sites in Bulgaria, France and 6 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Respiratory Physiology Under High Flow Therapy
The aim of this study is to gain knowledge about effects of high flow transnasal insufflation on various breathing parameters like intratracheal pressure conditions, CO2 elimination, breathing frequency and tidal volume.
- Trial name
- NCT01509703
- Testing
- High flow therapy
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Institut für Pneumologie Hagen Ambrock eV
Chronic Obstructive Pulmonary Disease, Lung Disease
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01215279
- Testing
- AZD2423
- Where
- 6 sites in Bulgaria, Slovakia
- Volunteers
- 63 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
- Trial name
- NCT02231359
- Testing
- Berodual® Respimat® solution for inhalation
- Volunteers
- 2,006 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks…
- Trial name
- PERFECT (NCT03496623)
- Testing
- Inhaled treprostinil solution
- Where
- 76 sites in United States, Argentina and 2 more
- Volunteers
- 188 people
- Sponsor
- United Therapeutics
COPD
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.
- Trial name
- AIRFLOW-3 (NCT03639051)
- Testing
- Targeted Lung Denervation (TLD), Optimal Medical Care
- Where
- 33 sites in United States, Austria and 4 more
- Volunteers
- 464 people
- Sponsor
- Nuvaira, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
This study will compare the efficacy of indacaterol versus placebo (i.e., rescue medication only) and tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD) who have not received maintenance COPD medication for…
- Trial name
- INITIATE (NCT01715311)
- Testing
- Indacaterol, Tiotropium
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00206167
- Testing
- Budesonide/formoterol pMDI, Formoterol Turbuhaler
- Where
- 216 sites in United States, Bulgaria and 7 more
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
An Investigation of the Past 10 Yrs Health Care for Primary Care Patients With Chronic Obstructive Pulmonary Disease
The aim of this study is to describe COPD health care and to assess demographics, concurrent diseases and mortality and the use of pharmaceuticals for a chronic obstructive pulmonary disease (COPD) population in real life in…
- Trial name
- PATHOS (NCT01146392)
- Where
- Sweden
- Volunteers
- 27,394 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One-Year Study
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00168844
- Testing
- Tiotropium Inhalation Solution
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00358436
- Testing
- Aclidinium bromide
- Where
- 120 sites in United States, Argentina and 5 more
- Volunteers
- 804 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.
The study will evaluate the pharmacokinetics (PK) of AZD6793 when administered alone and in combination with itraconazole in healthy adult participants.
- Trial name
- NCT06494644
- Testing
- AZD6793, Itraconazole, AZD6793+ Itraconazole
- Where
- Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Moderate to Severe COPD
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
- Trial name
- INDOS-B (NCT06531798)
- Testing
- Breztri Aerosphere
- Where
- 6 sites in India
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, COPD
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00463567
- Testing
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.)
- Where
- 344 sites in United States, Argentina and 10 more
- Volunteers
- 2,059 people
- Sponsor
- Novartis
COPD
Efficacy and Safety of AQX-1125 in Unstable COPD
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease…
- Trial name
- FLAGSHIP (NCT01954628)
- Testing
- AQX-1125
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Chronic Obstructive Pulmonary Disease
A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients
This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily [BID]) and a placebo control in moderate…
- Trial name
- NCT02272634
- Testing
- YPL-001 80 mg, YPL-001 160 mg
- Where
- 4 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Chronic Obstructive Pulmonary Disease
The Effect of NIV on QoL and Exercise Capacity in a COPD Exercise Rehabilitation Program
This trial hopes to demonstrate the effect of 4 weeks of outpatient exercise rehabilitation on COPD patients. In particular the effect on: the amount of daily physical activity Quality of life The 6-minute walk distance Time to…
- Trial name
- NCT02100709
- Testing
- BiLevel Noninvasive Ventilation
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- ResMed
COPD
7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01704404
- Testing
- TD-4208
- Where
- New Zealand
- Volunteers
- 62 people
- Sponsor
- Mylan Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.